NASDAQ:NTLA Intellia Therapeutics (NTLA) Stock Price, News & Analysis $7.06 -1.02 (-12.58%) As of 12:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Intellia Therapeutics Stock (NASDAQ:NTLA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Intellia Therapeutics alerts:Sign Up Key Stats Today's Range$7.08▼$7.8350-Day Range$8.07▼$12.2852-Week Range$7.04▼$28.18Volume3.06 million shsAverage Volume2.19 million shsMarket Capitalization$730.31 millionP/E RatioN/ADividend YieldN/APrice Target$37.56Consensus RatingModerate Buy Company OverviewIntellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Read More… Remove Ads Intellia Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScoreNTLA MarketRank™: Intellia Therapeutics scored higher than 89% of companies evaluated by MarketBeat, and ranked 96th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingIntellia Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 11 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageIntellia Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Intellia Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Intellia Therapeutics are expected to grow in the coming year, from ($5.07) to ($5.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intellia Therapeutics is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intellia Therapeutics is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntellia Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Intellia Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.07% of the float of Intellia Therapeutics has been sold short.Short Interest Ratio / Days to CoverIntellia Therapeutics has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Intellia Therapeutics has recently increased by 2.50%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntellia Therapeutics does not currently pay a dividend.Dividend GrowthIntellia Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.67 Percentage of Shares Shorted27.07% of the float of Intellia Therapeutics has been sold short.Short Interest Ratio / Days to CoverIntellia Therapeutics has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Intellia Therapeutics has recently increased by 2.50%, indicating that investor sentiment is decreasing. News and Social Media1.8 / 5News Sentiment0.29 News SentimentIntellia Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 35 news articles for Intellia Therapeutics this week, compared to 10 articles on an average week.Search InterestOnly 14 people have searched for NTLA on MarketBeat in the last 30 days. This is a decrease of -66% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Intellia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Intellia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $352,551.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of Intellia Therapeutics is held by insiders.Percentage Held by Institutions88.77% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Intellia Therapeutics' insider trading history. Receive NTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NTLA Stock News HeadlinesContact The Gross Law Firm by April 14, 2025 Deadline to Join Class Action Against Intellia Therapeutics, Inc.(NTLA)March 31 at 5:45 AM | prnewswire.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. ...March 29 at 3:11 PM | gurufocus.comMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of America…March 31, 2025 | Porter & Company (Ad)ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLAMarch 29 at 3:03 PM | globenewswire.comNTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud LawsuitMarch 29 at 9:00 AM | prnewswire.comWhat is William Blair's Estimate for NTLA Q2 Earnings?March 29 at 2:23 AM | americanbankingnews.comLevi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NTLAMarch 28 at 5:45 AM | prnewswire.comEquities Analysts Offer Predictions for NTLA Q1 EarningsMarch 28 at 2:17 AM | americanbankingnews.comSee More Headlines NTLA Stock Analysis - Frequently Asked Questions How have NTLA shares performed this year? Intellia Therapeutics' stock was trading at $11.66 at the beginning of 2025. Since then, NTLA shares have decreased by 30.8% and is now trading at $8.07. View the best growth stocks for 2025 here. How were Intellia Therapeutics' earnings last quarter? Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its earnings results on Thursday, November, 7th. The company reported ($1.34) EPS for the quarter, beating analysts' consensus estimates of ($1.37) by $0.03. The business's revenue was down 24.1% compared to the same quarter last year. When did Intellia Therapeutics IPO? Intellia Therapeutics (NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Intellia Therapeutics' major shareholders? Top institutional investors of Intellia Therapeutics include ARK Investment Management LLC (12.31%), Vanguard Group Inc. (10.00%), Regeneron Pharmaceuticals Inc. (3.64%) and Sumitomo Mitsui Trust Group Inc. (2.94%). Insiders that own company stock include John M Leonard, James Basta, Eliana Clark, David Lebwohl, Michael P Dube, Laura Sepp-Lorenzino and Glenn Goddard. View institutional ownership trends. How do I buy shares of Intellia Therapeutics? Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Intellia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intellia Therapeutics investors own include Chevron (CVX), Bristol-Myers Squibb (BMY), Comcast (CMCSA), NVIDIA (NVDA), Charles Schwab (SCHW), Meta Platforms (META) and Edwards Lifesciences (EW). Company Calendar Last Earnings11/07/2024Today3/31/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NTLA CIK1652130 Webwww.intelliatx.com Phone(857) 285-6200FaxN/AEmployees600Year FoundedN/APrice Target and Rating Average Stock Price Target$37.56 High Stock Price Target$90.00 Low Stock Price Target$9.00 Potential Upside/Downside+365.4%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)($5.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-481,190,000.00 Net MarginsN/A Pretax Margin-1,212.19% Return on Equity-49.34% Return on Assets-40.27% Debt Debt-to-Equity RatioN/A Current Ratio6.73 Quick Ratio6.73 Sales & Book Value Annual Sales$57.88 million Price / Sales14.43 Cash FlowN/A Price / Cash FlowN/A Book Value$11.73 per share Price / Book0.69Miscellaneous Outstanding Shares103,517,000Free Float98,590,000Market Cap$835.38 million OptionableOptionable Beta1.97 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:NTLA) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.